Intercept Pharmaceuticals | ICPT - Betriebsaufwand



Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amarin USD 51.48M 113K 2025-12
Amgen USD 5.9B 773M 2025-12
Arrowhead Research USD 223.22M 10.86M 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
Biogen USD 1.88B 81.4M 2025-09
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Galectin Therapeutics USD 11.29M 1.64M 2024-06
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Moderna USD 1.54B 259M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.8B 61M 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12